Alnuctamab With Mezigdomide

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
156
Last Updated
2 days ago
Am I Eligible

Participating Centers

There are 4 centers participating in this trial. Enter a location below to find the closet center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Alnuctamab
  • Dexamethasone
  • Mezigdomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Part A: Alnuctamab + Mezigdomide

Not yet accepting

Arm B1: Alnuctamab + Mezigdomide

Not yet accepting

Arm B2: Alnuctamab + Mezigdomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 354-2873

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.